Simris Group AB’s wholly owned subsidiary, Simris Biologics GmbH, today announced important progress in its ongoing preclinical study with Nuvisan, a leading European contract research and development organization.
Three proprietary Microcystin (MC)-based payloads were successfully generated in ADC format and evaluated in in-vitro efficacy studies. In two independent trials, one of the ADC variants demonstrated full-blown toxicity against the corresponding antigen-expressing cancer cell line, indicating complete elimination of cancer cells in response to treatment.
This payload candidate, now designated SIMRIS-121, having exhibited excellent potent in-vitro activity, will proceed to the next stage of the Nuvisan study—a dose-escalation in-vivo study to determine the maximum tolerated dose (MTD) of the ADC in mice.
“This is a significant milestone for our Microcystin ADC program,” said Dr. Alexis Roberts-McIntosh, CEO of Simris Group AB. “The clear demonstration of full cytotoxicity in one of our MC-ADC candidates confirms the therapeutic potential of our cyanobacterial payload platform. Together with Nuvisan’s deep expertise in preclinical development, we are advancing rapidly toward in-vivo validation.”
These results further support Simris’ mission to develop novel, cyanobacteria-derived toxin payloads with improved therapeutic windows and differentiated mechanisms of action for next-generation ADCs.
For more information about Simris Biologics, visit: https://simrisbiologics.com
For more information about Nuvisan, visit: https://www.nuvisan.com